Cullinan Therapeutics, Inc. (filed as Cullinan Oncology, Inc.) — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. The filing was signed November 8, 2023. Cullinan is a clinical-stage oncology company with no approved products and no product-sales revenue.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $33.8 million | $19.7 million | $113.3 million | $70.6 million |
| General and administrative expense | $11.0 million | $10.1 million | $31.9 million | $28.9 million |
| Net income (loss) | $(39.2) million | $(24.9) million | $(129.5) million | $136.3 million |
| Operating cash flow | Not separately provided | Not separately provided | $(116.1) million | $(101.7) million |
| Interest income | $5.9 million | $2.4 million | $15.7 million | $3.2 million |
At September 30, 2023, cash and cash equivalents were $64.8 million, short-term investments $401.6 million, and long-term investments $13.5 million. The company separately cited $466.4 million of cash, cash equivalents and short-term investments, plus $15.5 million of long-term investments and interest receivable. Total assets were $494.7 million; total liabilities were $25.9 million; stockholders’ equity was $468.8 million. No product margin is meaningful because the company had no product-sales revenue.
There was no income tax expense or benefit in 2023. The company reported $1.9 million of current liabilities for a convertible note and accrued interest, as well as $3.5 million due to Taiho under the collaboration agreement. Operating lease liabilities totaled $4.0 million. The filing reports no material legal proceedings.
Material changes versus the prior comparable period
- Q3 net loss widened to $39.2 million from $24.9 million, while nine-month results shifted from $136.3 million net income to a $129.5 million net loss. The 2022 nine-month profit included a $276.8 million gain from selling Cullinan Pearl, the subsidiary holding zipalertinib rights outside specified Asian territories.
- Q3 R&D expense rose $14.1 million year over year, chiefly from higher clinical and manufacturing costs, personnel, and equity compensation. Nine-month R&D rose $42.7 million, including the $25.0 million upfront CLN-418 license fee.
- Nine-month operating cash use increased by $14.5 million. Cash and cash equivalents fell from $156.2 million at year-end 2022 to $64.8 million; investment balances also shifted, with total investments rising to $415.1 million from $392.0 million.
- The company raised $38.4 million net through its at-the-market (ATM) offering during the first nine months; $85.6 million of offering capacity remained at September 30. It also exchanged 6.5 million common shares for 647,500 convertible preferred shares, each convertible into ten common shares subject to ownership limits.
Outlook, management commentary, and risks
- Management expects available cash, cash equivalents and investments to fund operations for at least 12 months from the financial statements’ issuance date. Cullinan expects continued operating losses and significant future R&D spending; actual runway may be shorter, and additional financing may be needed.
- Pipeline milestones stated in the filing include expected completion of enrollment in the pivotal REZILIENT1 Phase 2b portion of the zipalertinib study by year-end 2024; updated CLN-049 data in the second half of 2024; initial CLN-418 data in the second half of 2024; and initial CLN-617 Phase 1 dosing by year-end 2023. CLN-978’s Phase 1 trial began dosing in August 2023.
- For CLN-619, management reported preliminary monotherapy activity in heavily pretreated patients: among 22 evaluable patients receiving doses above 1 mg/kg, one had a confirmed complete response, two had confirmed partial responses, and seven had stable disease. These early observations are not evidence of established efficacy; the company planned further expansion and follow-up data.
- Zipalertinib development costs are shared equally with Taiho, with each party entitled to 50% of potential future U.S. pre-tax profits; Cullinan retains an option to co-commercialize in the U.S. The company also disclosed contingent milestone and royalty obligations under licensing arrangements, including potential Harbour development/regulatory and sales milestones and royalties for CLN-418.
- Key risks include clinical-trial outcomes, patient enrollment and timing, regulatory approval, manufacturing and third-party dependence, intellectual-property protection, competition, and the ability to obtain additional funding. Equity financing may dilute shareholders; other funding arrangements could require granting rights.
- The filing describes a $0.4 million impairment of the vacated Suite 520 lease asset group after cancellation of its sublease. The income statement presents the impairment line as $(0.44) million; investors may wish to verify the presentation and accounting treatment.
Important facts for investors to verify
- Whether clinical data and stated trial timelines for CLN-619, zipalertinib, CLN-049, CLN-418, CLN-978, and CLN-617 progress as anticipated.
- How operating burn, clinical-development spending, and investment maturities affect the stated cash runway and potential need for financing.
- Potential dilution from the remaining $85.6 million ATM capacity and conversion terms of the preferred stock.
- The timing and conditions of contingent collaboration milestones, royalties, and potential future economics with Taiho and Harbour.
- The reported lease-asset impairment line and the extent to which 2022’s Cullinan Pearl sale gain distorts year-over-year comparisons.